Does the media favor AVR or PDEX?

In the previous week, Anteris Technologies Global had 9 more articles in the media than Pro-Dex. MarketBeat recorded 12 mentions for Anteris Technologies Global and 3 mentions for Pro-Dex. Anteris Technologies Global's average media sentiment score of 0.33 beat Pro-Dex's score of 0.13 indicating that Anteris Technologies Global is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anteris Technologies Global 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Pro-Dex 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PDEX or TCMD?

In the previous week, Tactile Systems Technology had 1 more articles in the media than Pro-Dex. MarketBeat recorded 4 mentions for Tactile Systems Technology and 3 mentions for Pro-Dex. Tactile Systems Technology's average media sentiment score of 0.41 beat Pro-Dex's score of 0.13 indicating that Tactile Systems Technology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pro-Dex 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tactile Systems Technology 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer NNNN or PDEX?

Pro-Dex has a consensus target price of $74.00, indicating a potential upside of 12.70%. Given Pro-Dex's stronger consensus rating and higher possible upside, analysts clearly believe Pro-Dex is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Pro-Dex 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has stronger valuation & earnings, NNNN or PDEX?

Pro-Dex has higher revenue and earnings than Anbio Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 63.54 $6.40M N/A N/A Pro-Dex $77.55M 2.71 $13.66M $3.65 17.99

Which has better earnings and valuation, SGHT or PDEX?

Pro-Dex has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sight Sciences $77.36M 7.78 -$38.43M -$0.52 N/A Pro-Dex $77.55M 2.71 $13.66M $3.65 17.99

Is SGHT or PDEX more profitable?

Pro-Dex has a net margin of 15.12% compared to Sight Sciences' net margin of -32.13%. Pro-Dex's return on equity of 26.18% beat Sight Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Sight Sciences -32.13% -43.91% -22.20% Pro-Dex 15.12% 26.18% 16.69%

Does the media favor SGHT or PDEX?

In the previous week, Sight Sciences had 9 more articles in the media than Pro-Dex. MarketBeat recorded 12 mentions for Sight Sciences and 3 mentions for Pro-Dex. Sight Sciences' average media sentiment score of 0.34 beat Pro-Dex's score of 0.13 indicating that Sight Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sight Sciences 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Pro-Dex 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, PDEX or DCTH?

Pro-Dex has higher earnings, but lower revenue than Delcath Systems. Pro-Dex is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pro-Dex $77.55M 2.71 $13.66M $3.65 17.99 Delcath Systems $85.23M 8.39 $2.70M $0.16 128.44

Is PDEX or DCTH more profitable?

Pro-Dex has a net margin of 15.12% compared to Delcath Systems' net margin of 6.05%. Pro-Dex's return on equity of 26.18% beat Delcath Systems' return on equity. Company Net Margins Return on Equity Return on Assets Pro-Dex 15.12% 26.18% 16.69% Delcath Systems 6.05% 5.56% 4.98%

Does the media refer more to PDEX or DCTH?

In the previous week, Delcath Systems had 36 more articles in the media than Pro-Dex. MarketBeat recorded 39 mentions for Delcath Systems and 3 mentions for Pro-Dex. Delcath Systems' average media sentiment score of 0.74 beat Pro-Dex's score of 0.13 indicating that Delcath Systems is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pro-Dex 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Delcath Systems 10 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Pro-Dex (PDEX) Competitors

$65.66 -1.76 (-2.61%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$67.78 +2.12 (+3.23%)

As of 11/13/2026 07:34 PM Eastern

Compare

PDEX vs. AVR, TCMD, NNNN, SGHT, and DCTH

Should you buy Pro-Dex stock or one of its competitors? Pro-Dex's main competitors and comparable companies include Anteris Technologies Global (AVR), Tactile Systems Technology (TCMD), Anbio Biotechnology (NNNN), Sight Sciences (SGHT), and Delcath Systems (DCTH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Pro-Dex compare to Anteris Technologies Global?

Anteris Technologies Global (NASDAQ:AVR) and Pro-Dex (NASDAQ:PDEX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Pro-Dex has higher revenue and earnings than Anteris Technologies Global. Anteris Technologies Global is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anteris Technologies Global	$1.91M	276.65	-$94.14M	-$1.61	N/A
Pro-Dex	$77.55M	2.71	$13.66M	$3.65	17.99

Anteris Technologies Global has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market. Comparatively, Pro-Dex has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market.

Anteris Technologies Global presently has a consensus price target of $13.75, suggesting a potential upside of 153.69%. Pro-Dex has a consensus price target of $74.00, suggesting a potential upside of 12.70%. Given Anteris Technologies Global's higher possible upside, equities research analysts clearly believe Anteris Technologies Global is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anteris Technologies Global	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Pro-Dex	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

15.3% of Pro-Dex shares are held by institutional investors. 4.5% of Anteris Technologies Global shares are held by company insiders. Comparatively, 48.0% of Pro-Dex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Pro-Dex has a net margin of 15.12% compared to Anteris Technologies Global's net margin of -4,637.48%. Pro-Dex's return on equity of 26.18% beat Anteris Technologies Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anteris Technologies Global	-4,637.48%	-57.15%	-50.73%
Pro-Dex	15.12%	26.18%	16.69%

In the previous week, Anteris Technologies Global had 9 more articles in the media than Pro-Dex. MarketBeat recorded 12 mentions for Anteris Technologies Global and 3 mentions for Pro-Dex. Anteris Technologies Global's average media sentiment score of 0.33 beat Pro-Dex's score of 0.13 indicating that Anteris Technologies Global is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anteris Technologies Global	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Pro-Dex	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Pro-Dex beats Anteris Technologies Global on 10 of the 16 factors compared between the two stocks.

How does Pro-Dex compare to Tactile Systems Technology?

Pro-Dex (NASDAQ:PDEX) and Tactile Systems Technology (NASDAQ:TCMD) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Pro-Dex presently has a consensus target price of $74.00, indicating a potential upside of 12.70%. Tactile Systems Technology has a consensus target price of $36.80, indicating a potential upside of 37.26%. Given Tactile Systems Technology's higher possible upside, analysts plainly believe Tactile Systems Technology is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Tactile Systems Technology	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Pro-Dex has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market. Comparatively, Tactile Systems Technology has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

15.3% of Pro-Dex shares are owned by institutional investors. Comparatively, 83.4% of Tactile Systems Technology shares are owned by institutional investors. 48.0% of Pro-Dex shares are owned by insiders. Comparatively, 2.1% of Tactile Systems Technology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Tactile Systems Technology has higher revenue and earnings than Pro-Dex. Pro-Dex is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$77.55M	2.71	$13.66M	$3.65	17.99
Tactile Systems Technology	$356.42M	1.68	$19.09M	$1.03	26.03

Pro-Dex has a net margin of 15.12% compared to Tactile Systems Technology's net margin of 6.68%. Pro-Dex's return on equity of 26.18% beat Tactile Systems Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	15.12%	26.18%	16.69%
Tactile Systems Technology	6.68%	10.73%	8.53%

In the previous week, Tactile Systems Technology had 1 more articles in the media than Pro-Dex. MarketBeat recorded 4 mentions for Tactile Systems Technology and 3 mentions for Pro-Dex. Tactile Systems Technology's average media sentiment score of 0.41 beat Pro-Dex's score of 0.13 indicating that Tactile Systems Technology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pro-Dex	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tactile Systems Technology	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Tactile Systems Technology beats Pro-Dex on 9 of the 15 factors compared between the two stocks.

How does Pro-Dex compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and Pro-Dex (NASDAQ:PDEX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

Pro-Dex has a net margin of 15.12% compared to Anbio Biotechnology's net margin of 0.00%. Pro-Dex's return on equity of 26.18% beat Anbio Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Pro-Dex	15.12%	26.18%	16.69%

In the previous week, Pro-Dex had 2 more articles in the media than Anbio Biotechnology. MarketBeat recorded 3 mentions for Pro-Dex and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.82 beat Pro-Dex's score of 0.13 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Anbio Biotechnology	Very Positive
Pro-Dex	Neutral

Pro-Dex has higher revenue and earnings than Anbio Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	63.54	$6.40M	N/A	N/A
Pro-Dex	$77.55M	2.71	$13.66M	$3.65	17.99

15.3% of Pro-Dex shares are owned by institutional investors. 48.0% of Pro-Dex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Pro-Dex has a consensus target price of $74.00, indicating a potential upside of 12.70%. Given Pro-Dex's stronger consensus rating and higher possible upside, analysts clearly believe Pro-Dex is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pro-Dex	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Anbio Biotechnology has a beta of 5.72, meaning that its share price is 472% more volatile than the broader market. Comparatively, Pro-Dex has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market.

Summary

Pro-Dex beats Anbio Biotechnology on 11 of the 14 factors compared between the two stocks.

How does Pro-Dex compare to Sight Sciences?

Sight Sciences (NASDAQ:SGHT) and Pro-Dex (NASDAQ:PDEX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Pro-Dex has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$77.36M	7.78	-$38.43M	-$0.52	N/A
Pro-Dex	$77.55M	2.71	$13.66M	$3.65	17.99

55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 30.4% of Sight Sciences shares are owned by company insiders. Comparatively, 48.0% of Pro-Dex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Sight Sciences has a beta of 2.44, meaning that its stock price is 144% more volatile than the broader market. Comparatively, Pro-Dex has a beta of 0.12, meaning that its stock price is 88% less volatile than the broader market.

In the previous week, Sight Sciences had 9 more articles in the media than Pro-Dex. MarketBeat recorded 12 mentions for Sight Sciences and 3 mentions for Pro-Dex. Sight Sciences' average media sentiment score of 0.34 beat Pro-Dex's score of 0.13 indicating that Sight Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sight Sciences	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pro-Dex	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pro-Dex has a net margin of 15.12% compared to Sight Sciences' net margin of -32.13%. Pro-Dex's return on equity of 26.18% beat Sight Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-32.13%	-43.91%	-22.20%
Pro-Dex	15.12%	26.18%	16.69%

Sight Sciences currently has a consensus price target of $10.31, indicating a potential downside of 4.78%. Pro-Dex has a consensus price target of $74.00, indicating a potential upside of 12.70%. Given Pro-Dex's stronger consensus rating and higher probable upside, analysts plainly believe Pro-Dex is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pro-Dex	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Pro-Dex beats Sight Sciences on 10 of the 16 factors compared between the two stocks.

How does Pro-Dex compare to Delcath Systems?

Pro-Dex (NASDAQ:PDEX) and Delcath Systems (NASDAQ:DCTH) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Pro-Dex has a beta of 0.12, meaning that its stock price is 88% less volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

Pro-Dex presently has a consensus target price of $74.00, indicating a potential upside of 12.70%. Delcath Systems has a consensus target price of $29.33, indicating a potential upside of 42.74%. Given Delcath Systems' stronger consensus rating and higher probable upside, analysts clearly believe Delcath Systems is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Delcath Systems	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00

15.3% of Pro-Dex shares are owned by institutional investors. Comparatively, 61.1% of Delcath Systems shares are owned by institutional investors. 48.0% of Pro-Dex shares are owned by company insiders. Comparatively, 19.4% of Delcath Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Delcath Systems had 36 more articles in the media than Pro-Dex. MarketBeat recorded 39 mentions for Delcath Systems and 3 mentions for Pro-Dex. Delcath Systems' average media sentiment score of 0.74 beat Pro-Dex's score of 0.13 indicating that Delcath Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pro-Dex	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Delcath Systems	10 Very Positive mention(s)	3 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pro-Dex has a net margin of 15.12% compared to Delcath Systems' net margin of 6.05%. Pro-Dex's return on equity of 26.18% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	15.12%	26.18%	16.69%
Delcath Systems	6.05%	5.56%	4.98%

Pro-Dex has higher earnings, but lower revenue than Delcath Systems. Pro-Dex is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$77.55M	2.71	$13.66M	$3.65	17.99
Delcath Systems	$85.23M	8.39	$2.70M	$0.16	128.44

Summary

Delcath Systems beats Pro-Dex on 10 of the 16 factors compared between the two stocks.

Get Pro-Dex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PDEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PDEX vs. The Competition

Export

Metric	Pro-Dex	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$215.74M	$5.96B	$7.84B	$12.19B
Dividend Yield	N/A	1.68%	2.46%	4.53%
P/E Ratio	17.99	38.39	34.71	28.44
Price / Sales	2.71	5.57	8.66	5.84
Price / Cash	17.27	23.95	21.93	22.49
Price / Book	4.26	4.45	4.35	3.76
Net Income	$13.66M	$143.14M	$3.51B	$390.55M
7 Day Performance	3.97%	-1.25%	-1.49%	-0.33%
1 Month Performance	9.40%	-1.30%	-2.55%	-4.82%
1 Year Performance	104.61%	1.73%	0.92%	-5.83%

Pro-Dex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PDEX Pro-Dex	2.6981 of 5 stars	$65.66 -2.6%	$74.00 +12.7%	N/A	$215.74M	$77.55M	17.99	206	Analyst Upgrade
AVR Anteris Technologies Global	2.8138 of 5 stars	$5.60 -3.1%	$14.00 +150.0%	N/A	$563.31M	$1.91M	N/A	174	Earnings Report Analyst Forecast
TCMD Tactile Systems Technology	3.7932 of 5 stars	$24.78 +8.4%	$36.80 +48.5%	N/A	$518.06M	$329.52M	22.20	1,086	High Trading Volume
NNNN Anbio Biotechnology	0.8316 of 5 stars	$3.59 +2.3%	N/A	N/A	$505.06M	$8.65M	N/A	27	Positive News
SGHT Sight Sciences	2.4078 of 5 stars	$9.42 +3.0%	$9.25 -1.8%	N/A	$504.05M	$77.36M	N/A	186	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PDEX) was last updated on 11/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pro-Dex (PDEX) Competitors

PDEX vs. AVR, TCMD, NNNN, SGHT, and DCTH

How does Pro-Dex compare to Anteris Technologies Global?

Summary

How does Pro-Dex compare to Tactile Systems Technology?

Summary

How does Pro-Dex compare to Anbio Biotechnology?

Summary

How does Pro-Dex compare to Sight Sciences?

Summary

How does Pro-Dex compare to Delcath Systems?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDEX vs. The Competition

Pro-Dex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pro-Dex (PDEX) Competitors

PDEX vs. AVR, TCMD, NNNN, SGHT, and DCTH

How does Pro-Dex compare to Anteris Technologies Global?

Which has better valuation & earnings, AVR or PDEX?

Which has more volatility and risk, AVR or PDEX?

Do analysts prefer AVR or PDEX?

Do insiders and institutionals hold more shares of AVR or PDEX?

Is AVR or PDEX more profitable?

Does the media favor AVR or PDEX?

Summary

How does Pro-Dex compare to Tactile Systems Technology?

Do analysts prefer PDEX or TCMD?

Which has more risk and volatility, PDEX or TCMD?

Do insiders and institutionals believe in PDEX or TCMD?

Which has stronger earnings and valuation, PDEX or TCMD?

Is PDEX or TCMD more profitable?

Does the media refer more to PDEX or TCMD?

Summary

How does Pro-Dex compare to Anbio Biotechnology?

Is NNNN or PDEX more profitable?

Does the media favor NNNN or PDEX?

Which has stronger valuation & earnings, NNNN or PDEX?

Do institutionals and insiders have more ownership in NNNN or PDEX?

Do analysts prefer NNNN or PDEX?

Which has more volatility & risk, NNNN or PDEX?

Summary

How does Pro-Dex compare to Sight Sciences?

Which has better earnings and valuation, SGHT or PDEX?

Do institutionals & insiders have more ownership in SGHT or PDEX?

Which has more risk and volatility, SGHT or PDEX?

Does the media favor SGHT or PDEX?

Is SGHT or PDEX more profitable?

Do analysts rate SGHT or PDEX?

Summary

How does Pro-Dex compare to Delcath Systems?

Which has more risk and volatility, PDEX or DCTH?

Do analysts recommend PDEX or DCTH?

Do institutionals and insiders believe in PDEX or DCTH?

Does the media refer more to PDEX or DCTH?

Is PDEX or DCTH more profitable?

Which has preferable earnings & valuation, PDEX or DCTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDEX vs. The Competition

Pro-Dex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools